Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
DiscussionIf early administration of inhaled dornase alfa actually reduces the incidence of moderate-to-severe hypoxaemia in patients with severe trauma, this new therapeutic strategy may be easily implemented in many clinical trauma care settings. This treatment may facilitate ventilator weaning, reduce the burden of trauma-induced lung inflammation and facilitate recovery and rehabilitation in severe trauma patients.Trial registrationClinicalTrials.gov,NCT03368092. Registered on 11 December 2017. (Source: Trials)
Source: Trials - March 17, 2020 Category: Research Source Type: clinical trials
A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme ® in Healthy Subjects
Condition: Healthy Subjects Interventions: Biological: JHL1922; Biological: dornase alfa Sponsor: JHL Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2018 Category: Research Source Type: clinical trials
